<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02280603</url>
  </required_header>
  <id_info>
    <org_study_id>DA4001_AGAP_POC</org_study_id>
    <nct_id>NCT02280603</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application</brief_title>
  <official_title>A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore the efficacy and safety of DA-4001 after topical
      application in male patients with androgenetic alopecia

      Design : Randomized, double-blind, active-controlled study

      Investigational Product : Finasteride, minoxidil
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in target area hair count per cm2 at week 24, as assessed by phototrichogram</measure>
    <time_frame>baseline and week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in target area hair count per cm2 at week 16, as assessed by phototrichogram</measure>
    <time_frame>Baseline and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of target area hair count per cm2 at week 16 and week 24, as assessed by phototrichogram</measure>
    <time_frame>Baseline, week 16,and week24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate of target area mean hair diameter at week 16 and week 24, as assessed by phototrichogram</measure>
    <time_frame>Baseline, week 16, and week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>DA-4001C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DA-4001C is administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% minoxidil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5% minoxidil is administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-4001C</intervention_name>
    <description>1ml by topical application twice a day</description>
    <arm_group_label>DA-4001C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% minoxidil</intervention_name>
    <description>1ml by topical application twice a day</description>
    <arm_group_label>5% minoxidil</arm_group_label>
    <other_name>minoxyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Basic and specific(BASP) classification : basic type is M2 or C2 and specific type is
             V1,V2 or F1,F2

        Exclusion Criteria:

          -  Evidence of hair loss other than androgenetic alopecia

          -  Use of finasteride, dutasteride within previous 12 months

          -  Use of minoxidil within previous 6 months

          -  Use of androgenic or anti-androgenic agents within previous 6 months

          -  Use of steroid agents for local application to scalp or systemic application within
             previous 1 month

          -  History of hair transplantation, scalp reduction

          -  Coronary artery disease, arrhythmia, congestive heart failure, valvular haert disease,
             angina pectoris
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hoon Kang, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The catholic univ. of korea, St.Paul's hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Dongdaemun-gu</state>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

